

## 32-3778: EXOSC10 Recombinant Protein

<b>Uniprot ID :</b>	Q01780
<b>Alternative Name :</b>	Exosome component 10,Polymyositis/scleroderma autoantigen 2,Autoantigen PM/ScI 2,Polymyositis/scleroderma autoantigen 100 kDa,PM/ScI-100,P100 polymyositis-scleroderma overlap syndrome-associated autoantigen,EXOSC10,PMSC1,PMSC2,p2,p3,p4,R

### Description

Source : Sf9 insect cells. EXOSC10 Human Recombinant produced in SF9 is a glycosylated, polypeptide chain having a molecular mass of 120 kDa. EXOSC10 is expressed with a -6xHis tag and purified by proprietary chromatographic techniques. EXOSC10 is a nucleolar protein and represents one crucial component of the so-called 'PM/ScI complex' or 'nuclear exosome', which is an RNA-processing complex consisting of a number of exoribonucleases (not to be confused with certain multivesicular bodies which are shed by cultured cells into the culture fluid and are also called exosomes). Autoantibodies against EXOSC10 occur in patients suffering from polymyositis, scleroderma or polymyositis/scleroderma overlap syndromes. While antibodies to other components of the exosome complex (PM/ScI 75, several Rrp proteins) can be found in some sera, practically all patients with autoantibodies against the PM/ScI complex are positive for EXOSC10 antibodies, making this specificity an important marker. The presence of EXOSC10 autoantibodies is a comparatively 'good' prognostic sign in polymyositis/scleroderma overlap syndrome unlike the poor prognosis seen when other myositis and systemic sclerosis specific autoantibodies are present.

### Product Info

<b>Amount :</b>	20 µg
<b>Purification :</b>	Greater than 70% as determined by SDS-PAGE.
<b>Content :</b>	EXOSC10 is supplied at a concentration of 0.8mg/ml in 20mM HEPES, pH-7.5, 100mM NaCl, 0.01mM EDTA, 0.02% SDS.
<b>Storage condition :</b>	Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.
<b>Amino Acid :</b>	mappstrepr vlsatsatks dgemvlpqfp ddsfvkfal gsvvavtkas gglpqfgdey 61 dfyrsfpgfq afcetqgdrl lqcmrvmqy hgcrsnikdr skvteledkf dllvdandvi 121 lervgilde asgvnknqqp vlpaglvvpk tvvsswnrka aeygkkakse tfrllhakni 181 irpqlkrek idsntpflp kifkpnakq plpqalsker rerpqdrped ldvppaladf 241 ihqqrqqve qdmfahpyqy elnhftpada vlqkppqly rpieetpCHF issldelvel 301 nekllncqef avdlehhsyr sflgltclmq istrtedfii dtlelrsdmy ilnesltdpa 361 ivkvfhgads diewlqkdfg lyvnmfdth qaarllnlgr hsl dhllkly cnvdsnkqyq 421 ladwirrplp eemlsyardd thyllyiydk mrlmwergrn gqpvlqvww qrsrdiclk 481 fikpiftdes ylelyrkqkk hlntqqltaf qlfawrdkt arredesygy vlpnhmmiki 541 aeelpkepqq iiaacnpvpp lvrqqinemh lliqqaremp llksevaagv kksqplpsae 601 rlenlfgph dchshappdgy piiptsgsvp vqkqaslfpd ekednllgtt cliataviti 661 fnepsaedsk kgpltvakkk aqnimesfen pfrmflpslg hrapsqaak fdpstkiyei 721 snrwklaqvq vqkdskeavk kkaaeqtaar eqakeackaa aeqaisvrqq vvlenaakkr 781 eratsdprtt eqkqekkrk iskkpkdpep pekeftpydy sqsdfkafag nskskvssqf 841 dpnkqtpsgk kciaakkikq svgnksmsfp tgksdrgrfy nwpqr